Results 201 to 210 of about 913,105 (403)

Process development priorities for scaling up direct microbial conversion of sugars into value‐added biochemicals

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The study identified process development priorities toward the feasible production of five value‐added biochemicals in a sugarcane biorefinery based on achievable bioconversion performances. Multiple process scenarios using A‐molasses as feedstock were simulated in Aspen Plus® via direct microbial conversions.
Manasseh K. Sikazwe   +2 more
wiley   +1 more source

Dynamics of aroma profiling and emotional response for premium green tea. [PDF]

open access: yesNPJ Sci Food
Qiu T   +11 more
europepmc   +1 more source

PERBANDINGAN METODE PROJECTED UNIT CREDIT DAN INDIVIDUAL LEVEL PREMIUM DALAM PEMBIAYAAN DANA PENSIUN

open access: diamond, 2023
Kartika Olivia Pingkan Rembet   +3 more
openalex   +2 more sources

The Exporter Wage Premium Reconsidered Destinations, Distances and Linked Employer-Employee Data [PDF]

open access: yes
This study uses detailed, reliable and up-to-date linked employer-employee data that take account of both the demand and the supply side of the labor market to challenge the conventional wisdom of a universal exporter wage premium.
Achim Schmillen
core  

Market potential of biobased chemicals: a qualitative network analysis of adoption dynamics in South Africa’s bioeconomy

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The premise of a bioeconomy is the replacement of nonrenewable and unsustainable fossil‐derived resources and associated technologies with more sustainable alternatives. The adoption of biobased chemicals contributes toward the growth of a bioeconomy and is dependent on market and industry requirements.
Prisha Mandree   +2 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy